New hope for tough stomach cancers: experimental combo targets Hard-to-Treat cases
NCT ID NCT04768686
Summary
This study tested whether adding an experimental drug called FLX475 to an existing immunotherapy (pembrolizumab) could help control advanced stomach cancer. It enrolled about 90 patients whose cancer had progressed despite previous treatments, including separate groups based on their cancer's virus status. Researchers measured whether tumors shrank and how long the treatment kept the cancer from worsening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
-
Gangnam Severance Hospital
Seoul, South Korea
-
Hanllym University Medical Center
Anyang-si, Gyeonggi-do, South Korea
-
Korea University Guro Hospital
Seoul, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital
Seoul, South Korea
-
The Catholic University of Korea St. Vincent Hospital
Suwon, Gyeonggi-do, South Korea
Conditions
Explore the condition pages connected to this study.